QUOTED. 24 September 2020. Colleen Kraft
Cognoa said it will submit its AI-powered digital app for early detection of autism for de novo clearance with the US FDA. See what the company’s senior medical director of clinical adoption said about it here.
“A clinically validated, FDA-cleared digital assessment platform would empower pediatricians to take definitive action on parental concerns. They would be able to diagnose ASD much more efficiently with actionable information to drive the clinical management of the one in every 54 children with ASD and ensure that these children receive access to the appropriate care and treatment.” – Colleen Kraft, senior medical director of clinical adoption, Cognoa
- Find out more: Cognoa Seeks De Novo Clearance For AI-Powered Diagnostic App For Autism After Successful Study
Click here for a free trial of Medtech Insight